|
|
|
|
|
|
Sponsored by: |
Barzilai Medical Center |
Information provided by: | Barzilai Medical Center |
ClinicalTrials.gov Identifier: | NCT00372359 |
The purpose of this study is to find out whether prolonged treatment with methylphenidate has any adverse effect on cardiac functions and measurements.
Condition |
Attention Deficit Disorder With Hyperactivity Attention Deficit Disorder Attention Deficit Hyperactivity Disorder Attention Deficit Disorders With Hyperactivity Attention Deficit Hyperactivity Disorders |
MedlinePlus related topics: | Attention Deficit Hyperactivity Disorder |
ChemIDplus related topics: | Methylphenidate hydrochloride Methylphenidate |
Study Type: | Observational |
Study Design: | Screening, Cross-Sectional, Case Control, Retrospective Study |
Estimated Enrollment: | 50 |
Study Start Date: | August 2006 |
Estimated Study Completion Date: | August 2006 |
Attention deficit hyperactivity disorder (ADHD) is the most common neurobehavioral condition of childhood, with symptoms consisting of inattentiveness, impulsivity and hyperactivity. The diagnosis relies on subjective criteria since there is no objective test for ADHD. Stimulants are the recommended treatment, during the last 2 decades both the rate of its use has increased, and the age for starting treatment has decreased. Adverse side effects have been few, none of which were serious.
Recently, regulators of the Food and Drug Administration (FDA) have been told on forty deaths among patients who took stimulants through 2003. Accordingly, a subcommittee of the FDA recommended that prescription drugs to treat ADHD should be accompanied by strong 'black-box' warnings that they may increase the risk of heart problems in some patients.
To date, there does not appear to have been any study that has evaluated cardiac functions in these patients. In this study we will evaluate the possible long term effect of methylphenidate on cardiac functions, as to provide more knowledgeable basis for decisions on the treatment of ADHD patients with methylphenidate.
Children age 8-18 years who were treated on methylphenidate for more then five years will be allocated in outpatient clinics. Complete EKG and echocardiographic examinations will be performed and cardiac functions, left ventricular mass and left ventricular muscle width will be compared to the normal range of values. The results will give us, for the first time, a basis to support or reject the causative relationship between these drugs and severe cardiac problems.
Ages Eligible for Study: | 8 Years to 18 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Children with ADHD aged 8-18 years who are taking methylphenydate (Ritalin©, Ritalin SR©, Ritalin LA©) for more than 5 years.
Exclusion Criteria:
Children with any known heart disease or anomaly. Children whose ADHD is part of a syndrome or are mentally retarded. Children that are on any other chronic medications.
Contact: Shraga Aviner, MD, PhD | 972 3 674 5165 | aviners@barzi.health.govb.il |
Contact: Olga Kissilgof, MD | 972 8 674 5261 |
Israel | |||||
Pediatric Day Care Center, The Barzilai Medical Center | Recruiting | ||||
Ashkelon, Israel, 78306 | |||||
Contact: Shraga Aviner, MD, PhD 972 8 674 5165 aviners@barzi.health.gov.il | |||||
Contact: Olga Kissilgof, MD 972 8 674 5261 | |||||
Principal Investigator: Shraga Aviner, MD, PhD | |||||
Sub-Investigator: Olga Kissilgof, MD |
Barzilai Medical Center |
Principal Investigator: | Shraga Aviner, MD, PhD | The Barzilai Medical Center, Ashkelon, Israel |
Study ID Numbers: | BAR1400 |
First Received: | September 3, 2006 |
Last Updated: | September 3, 2006 |
ClinicalTrials.gov Identifier: | NCT00372359 |
Health Authority: | Israel: Ministry of Health |
|
|
|
|
|